Post by
Noteable on Aug 03, 2022 9:42am
ONCY bispecific in development (pelareorep x CD3)
May 2021 - Collaborative preclinical studies with LUMC is evaluating the combination of pelareorep-CD3-bispecific antibody combinations in breast and pancreatic tumor models.
Pelareorep's clinically demonstrated ability to recruit T cells to solid tumors provides a strong rationale for these studies, as CD3-bispecific antibodies are designed to facilitate cancer-killing by simultaneously engaging both T cells and tumor tissue.
Prior preclinical studies in breast and pancreatic cancer models also support this collaboration, as they have shown that the addition of pelareorep to CD3-bispecific antibody therapy results in cancer regression and prolonged survival.
https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-first-quarter-development-highlights-and-financial-results-301286355.html
Roche's Lunsumio is the first CD20xCD3 bispecific antibody approved anywhere.
https://www.fiercepharma.com/pharma/roches-bispecific-blood-cancer-drug-lunsumio-treads-car-ts-turf-global-first-nod
Comment by
westcoast1000 on Aug 06, 2022 11:43am
"Reovirus and bispecific antibodies are a true tumor-killer combo that would not be effective without each other.” - Dr. Nadine van Montfoort, group leader of viro-immunotherapy of cancer – at the Leiden University Medical Center (LUMC) in the Netherlands. This is a very important statement that Noteabele has posted.
Comment by
westcoast1000 on Aug 06, 2022 7:50pm
Building on my previous post: If the big pharma world collectively accepts the statement of Dr. von Monfoort, our subjective expected value as a company, in terms of medium term NPV, should perhaps be double what people thought previously, IMHO.
Comment by
Noteable on Aug 07, 2024 9:16pm
This is how one should consider the much broader and increasing potential of pelareorep in combination with multiple cancer agents.